An educational glycemic-control stack built on a single GLP-1 — the foundation of modern type-2 management.
GLP-1 receptor agonists transformed type-2 diabetes management by combining glycemic control with weight loss and cardiovascular benefit. Semaglutide is the anchor here for its extensive cardiovascular-outcomes data; it's run as a single agent, titrated slowly.
This overlaps the fat-loss stacks but frames the goal as glycemic control. Critically: type-2 diabetes is a medical diagnosis managed by a clinician — this page explains the mechanism, it doesn't replace a prescription or monitoring.
| Compound | Role | Dose | Frequency |
|---|---|---|---|
| Semaglutide GLP-1 agonist; strong CV-outcomes data. Prescription-managed. | Primary | 0.25mg starting, titrate to 1-2.4mg weekly | Once weekly (same day each week) |